Houston, we have a problem — and it's helping local startups have access to funding. Photo by Zview/Getty Images

A few weeks ago, Mayor of Houston Sylvester Turner and Station Houston CEO Gabriella Rowe proclaimed that Houston's up-and-coming innovation ecosystem was no longer up and coming: It had arrived. But what preceded that proclamation was years of figuring out what it was Houston could do to get to this point.

"We're the fourth largest city in the United States, and in 2015 were ranked 20th out of 25 ecosystems," Rowe says at a panel at the 2019 SXSW Interactive festival.

Following that shocking news, Rowe says the city's focus was on building tools — accelerators, incubators, education — but nowhere did anyone talk about funding. Now, years later, with plenty of accelerators, workspaces, and educational programs, Rowe says Houston now has a great pipeline of companies, but the problem is finding funding for them to tap into.

Entrepreneurs are looking for three things when it comes to finding ways to fund their companies, according to Rowe. They want it to be accessible capital — not something they have to take a class on to figure out how to get to it. They also want it to be impactful and local to where their headquarters is.

"When I think about accessible, impactful, and local, I think, well, not a lot falls into that category [in Houston]," Rowe says. "We're not doing it particularly well right now."

It's a structural problem, according to Rowe. While the city has built up its entrepreneurial climate, it hasn't yet made the same effort with investors.

"Even if we have one or two funds, we need an ecosystem that supports funding in the same way we have an ecosystem that supports entrepreneurs," she says.

Joe Milam, founder of Austin-based AngelSpan, an early stage investor relations platform, says the issue in Houston — and Austin — is that industries can be siloed. There's a huge need for an honest broker to connect the dots across the city, and that person needs to be impartial.

"You gotta care about your community first, before you care about your own agenda," Milam says. "Otherwise, you're going to flounder like Houston has, and how Austin still does."

One thing everyone agreed on during the Saturday, March 9, panel was that Houston has a lot of money, but it's been sitting on the sidelines. The mission is, in addition to bringing in venture capital firms, finding ways to engage money that's already in town.

"We have to produce tools to enable that capital that's hiding," Rowe says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

This Houston suburb named one of 10 newest boomtowns in U.S.

Booming 'Burb

What do you get when you combine a city's surge in population, housing growth, and economy? For the Houston suburb of Conroe, it adds up to being America's No. 9 newest boomtown, according to a new survey from SmartAsset.

The personal finance website's just-released report analyzed more than 400 U.S. cities with populations of 65,000 or more to identify places experiencing rapid growth based on five-year changes in economic output, housing units, and labor force size.

Texas is home to the second-highest concentration of new boomtowns in America with 18 out of 75 located in the Lone Star State. Only Florida ranks higher than Texas by just one.

However, Texas nearly locked out the top five most bustling boomtowns in America. Austin suburb Georgetown topped the list, and its Central Texas neighbors New Braunfels (No. 2) and Leander (No. 4) ranked close behind. Dallas-Fort Worth mid-city Lewisville claimed the No. 5 spot. Lehi, Utah ranked in third place.

Conroe has soared in popularity as one of America's most sought-after suburbs over the last several years, boosted by its renter-friendliness and its livability among the millennial generation.

Conroe has seen a 37 percent increase in housing units from 2019 to 2024, with its labor force growing by 33 percent during that time. SmartAsset also determined that Montgomery County's economic output grew at compound annual rates of 4.9 percent.

The report says population booms and "expanding business activity" can create "visible momentum" for an up-and-coming city, but these fast changes can alter a city in ways residents may not expect.

"In recent years, some American cities stand out for attracting people, investment and development at a pace that sets them apart," the report said. "Boomtown status does not mean growth benefits everyone equally, but it does reflect a city’s expanding economic capacity and the new opportunities that come with it."

America's top 10 new boomtowns are:

  • No. 1 – Georgetown
  • No. 2 – New Braunfels
  • No. 3 – Lehi, Utah
  • No. 4 – Leander
  • No. 5 – Lewisville
  • No. 6 – Palm Coast, Florida
  • No. 7 – Nampa, Idaho
  • No. 8 – McKinney
  • No. 9 – Conroe
  • No. 10 – Frisco
---

This article originally appeared on CultureMap.com.

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.